Developing New Medicines to Fight HPV Infection
Official title: Small-Molecule Covalent E6 Antagonists for Treatment of HPV Infection
Funded at Indiana University Indianapolis · NIH-11078681 · Data updated 2026-11-12
This research looks for new medicines that can stop the human papillomavirus (HPV) from causing cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project start | May 1, 2021 |
| Project end | April 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $657,376 |
| NIH project number | 5R01CA252715-05 |
| Project ID | NIH-11078681 on NIH RePORTER |
Who could benefit from this research
✓Could help
This foundational research is aimed at eventually helping patients who have high-risk HPV infections or HPV-associated cancers.
✕Less likely to help
Patients whose conditions are not related to high-risk HPV infection would not directly benefit from this specific treatment strategy.
What this research studies
High-risk human papillomavirus (HPV) types are linked to many cancers, including those of the cervix, anus, and throat. A specific HPV protein, called E6, is crucial for the virus to cause these cancers. Our scientists are working to create tiny molecules that can attach to the E6 protein and prevent it from doing its job. We use advanced computer modeling and lab tests to design and improve these potential new medicines. The aim is to develop highly effective treatments that can stop HPV-related cancer development.
Why it matters
Potential benefit: If successful, this work could lead to new medications that directly target and stop HPV, potentially preventing or treating HPV-associated cancers.
How similar studies have gone: Initial lab findings have shown promise with similar small molecules effectively targeting the E6 protein.
Where this research is happening
-
Indiana University Indianapolis
Indianapolis, United States Active
Researchers
- Principal investigator: Androphy, Elliot J. — Indiana University Indianapolis
- Study coordinator: Androphy, Elliot J.
Related research
Other NIH-funded projects on the same topics.
-
Epigenetics of oral HPV-related mouth and throat cancer in people with HIV in Nigeria
This project looks for DNA markers in people living with HIV in Nigeria to find who has or might develop HPV-related mouth and throat cancers.
-
Antibodies and vaginal bacteria in HPV-related cervical changes
This project looks at whether antibodies bind different vaginal bacteria in women with HPV or cervical cell changes to understand why some women develop more serious lesions.
-
Oral bacteria, gum disease, and oral HPV in people living with HIV
This project looks at how the mouth’s bacteria and gum disease relate to oral HPV in people with HIV, and what immune factors might be involved.
-
How HIV Treatment Might Change Oral HPV Risk
A study explored how antiretroviral therapy for HIV could affect the mouth’s lining and the chance of catching oral HPV, with participants including people living with HIV on ART and people using ART for PrEP.
-
Understanding how the penile cancer microbiome and p16 relate to HPV and outcomes across diverse patients
This project will look at how the tiny microbes living in penile tumors, p16 protein levels, high-risk HPV, and clinical outcomes are connected across patients from different regions.
-
Understanding how HIV medication affects oral HPV infection
This research explores if medications for HIV or HIV prevention might make people more likely to get oral human papillomavirus (HPV) infections.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.